Caroline Weydert

Caroline Weydert

Auto-generated profile, based on publicly available information

Caroline Weydert

Division of Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
BDBelete Desimmie
Belete Desimmie
RSRik Schrijvers
Rik Schrijvers
JDJonas Demeulemeester
Jonas Demeulemeester
DBDoortje Borrenberghs
Doortje Borrenberghs
CWCaroline Weydert
Caroline Weydert
ZDZeger Debyser
Zeger Debyser
Background: LEDGINs are novel allosteric HIV integrase (IN) inhibitors that target the lens epithelium-derived growth factor (LEDGF)/p75 binding pocket of IN. They block HIV-1 integration by abrogating the interaction between LEDGF/p75 and IN as well as by allosterically inhibiting the catalytic activity of IN. Results: Here we demonstrate that LEDGINs reduce the replication capacity of HIV particles produced in their presence. We systematically studied the molecular basis of this late effect of LEDGINs and demonstrate that HIV virions produced in their presence display a severe replication defect. Both the late effect and the previously described, early effect on integration contribute to LEDGIN antiviral activity as shown by time-of-addition, qPCR and infectivity assays. The late effect phenotype requires binding of LEDGINs to integrase without influencing proteolytic cleavage or production of viral particles. LEDGINs augment IN multimerization during virion assembly or in the released viral particles and severely hamper the infectivity of progeny virions. About 70% of the particles produced in LEDGIN-treated cells do not form a core or display aberrant empty cores with a mislocalized electron-dense ribonucleoprotein. The LEDGIN-treated virus displays defective reverse transcription and nuclear import steps in the target cells. The LEDGIN effect is possibly exerted at the level of the Pol precursor polyprotein. Conclusion: Our results suggest that LEDGINs modulate IN multimerization in progeny virions and impair the formation of regular cores during the maturation step, resulting in a decreased infectivity of the viral particles in the target cells. LEDGINs thus profile as unique antivirals with combined early (integration) and late (IN assembly) effects on the HIV replication cycle.

1 June 2016 in EBioMedicine
Verified
Journal Article
Open access
LVLenard S. Vranckx
Lenard S. Vranckx
JDJonas Demeulemeester
Jonas Demeulemeester
SSSuha Saleh
Suha Saleh
ABAnnegret Boll
Annegret Boll
GVGerlinde Vansant
Gerlinde Vansant
ZDZeger Debyser
Zeger Debyser
Persistence of latent, replication-competent Human Immunodeficiency Virus type 1 (HIV-1) provirus is the main impediment towards a cure for HIV/AIDS (Acquired Immune Deficiency Syndrome). Therefore, different therapeutic strategies to eliminate the viral reservoirs are currently being explored. We here propose a novel strategy to reduce the replicating HIV reservoir during primary HIV infection by means of drug-induced retargeting of HIV integration. A novel class of integration inhibitors, referred to as LEDGINs, inhibit the interaction between HIV integrase and the LEDGF/p75 host cofactor, the main determinant of lentiviral integration site selection. We show for the first time that LEDGF/p75 depletion hampers HIV-1 reactivation in cell culture. Next we demonstrate that LEDGINs relocate and retarget HIV integration resulting in a HIV reservoir that is refractory to reactivation by different latency-reversing agents. Taken together, these results support the potential of integrase inhibitors that modulate integration site targeting to reduce the likeliness of viral rebound.

28 April 2017 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
PJPeter Janssens
Peter Janssens
CWCaroline Weydert
Caroline Weydert
SRStephanie De Rechter
Stephanie De Rechter
KWKarl Martin Wissing
Karl Martin Wissing
MLMax Christoph Liebau
Max Christoph Liebau
DMDjalila Mekahli
Djalila Mekahli

12 February 2015 in Retrovirology
Verified
Journal Article
Open access
PDF file
BDBelete Desimmie
Belete Desimmie
CWCaroline Weydert
Caroline Weydert
RSRik Schrijvers
Rik Schrijvers
SVSofie Vets
Sofie Vets
JDJonas Demeulemeester
Jonas Demeulemeester
ZDZeger Debyser
Zeger Debyser
The dynamic interaction between HIV and its host governs the replication of the virus and the study of the virus-host interplay is key to understand the viral lifecycle. The host factor lens epithelium-derived growth factor (LEDGF/p75) tethers the HIV preintegration complex to the chromatin through a direct interaction with integrase (IN). Small molecules that bind the LEDGF/p75 binding pocket of the HIV IN dimer (LEDGINs) block HIV replication through a multimodal mechanism impacting early and late stage replication including HIV maturation. Furthermore, LEDGF/p75 has been identified as a Pol interaction partner. This raised the question whether LEDGF/p75 besides acting as a molecular tether in the target cell, also affects late steps of HIV replication. LEDGF/p75 is recruited into HIV-1 particles through direct interaction with the viral IN (or Pol polyprotein) and is a substrate for HIV-1 protease. Incubation in the presence of HIV-1 protease inhibitors resulted in detection of full-length LEDGF/p75 in purified viral particles. We also demonstrate that inhibition of LEDGF/p75-IN interaction by specific mutants or LEDGINs precludes incorporation of LEDGF/p75 in virions, underscoring the specificity of the uptake. LEDGF/p75 depletion did however not result in altered LEDGIN potency. Together, these results provide evidence for an IN/Pol mediated uptake of LEDGF/p75 in viral particles and a specific cleavage by HIV protease. Understanding of the possible role of LEDGF/p75 or its cleavage fragments in the viral particle awaits further experimentation.

1 September 2011 in Journal of Molecular Biology
Verified
Journal Article
Closed access
Longguang JiangLongguang Jiang
Longguang Jiang
ASAnna S.P. Svane
Anna S.P. Svane
HSHans Peter Sørensen
Hans Peter Sørensen
JJJan K. Jensen
Jan K. Jensen
MHMasood Hosseini
Masood Hosseini
PAPeter A. Andreasen
Peter A. Andreasen

11 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CWCaroline Weydert
Caroline Weydert
BHBart Van Heertum
Bart Van Heertum
LDLieve Dirix
Lieve Dirix
SHStéphanie De Houwer
Stéphanie De Houwer
FWFlore De Wit
Flore De Wit
ZDZeger Debyser
Zeger Debyser
The human immunodeficiency virus (HIV) depends on cellular proteins, so-called cofactors, to complete its replication cycle. In search for new therapeutic targets we identified the DNA and RNA binding protein Y-box-binding Protein 1 (YB-1) as a cofactor supporting early and late steps of HIV replication. YB-1 depletion resulted in a 10-fold decrease in HIV-1 replication in different cell lines. Dissection of the replication defects revealed that knockdown of YB-1 is associated with a 2- to 5-fold decrease in virion production due to interference with the viral RNA metabolism. Using single-round virus infection experiments we demonstrated that early HIV-1 replication also depends on the cellular YB-1 levels. More precisely, using quantitative PCR and an in vivo nuclear import assay with fluorescently labeled viral particles, we showed that YB-1 knockdown leads to a block between reverse transcription and nuclear import of HIV-1. Interaction studies revealed that YB-1 associates with integrase, although a direct interaction with HIV integrase could not be unambiguously proven. In conclusion, our results indicate that YB-1 affects multiple stages of HIV replication. Future research on the interaction between YB-1 and the virus will reveal whether this protein qualifies as a new antiviral target.